Filtered By:
Drug: Taxotere

This page shows you your search results in order of date. This is page number 17.

Order by Relevance | Date

Total 2208 results found since Jan 2013.

RGD-directed 24  nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors
J Control Release. 2023 Jun 23:S0168-3659(23)00406-6. doi: 10.1016/j.jconrel.2023.06.032. Online ahead of print.ABSTRACTNanomedicines while showing a great potential in improving the performance of chemotherapeutics like docetaxel (DTX) are distressed by a high liver deposition and poor tumor penetration, which might not only cause liver toxicity but also moderate therapeutic effect. Herein, we report that cRGD-directed 24 nm disulfide-crosslinked micellar docetaxel (cRGD-MDTX) presents low liver accumulation, high tumor uptake, and deep tumor penetration, leading to potent suppression of different solid tumors. cRGD-MDTX ...
Source: Cancer Control - June 25, 2023 Category: Cancer & Oncology Authors: Wencheng Yan Beibei Guo Zhe Wang Jiangtao Yang Zhiyuan Zhong Fenghua Meng Source Type: research

Improved Antitumor Efficacy of a Dextran-based Docetaxel-Coupled Conjugate Against Triple-Negative Breast Cancer
CONCLUSION: This dual-drug C-DDD has the potential to become a candidate for clinical application through the optimization of the linker.PMID:37349996 | DOI:10.2174/1567201820666230622105503
Source: Current Drug Delivery - June 23, 2023 Category: Drugs & Pharmacology Authors: Hongshuai Lv Weiping Jia Peng Dong Jiaojiao Liu Si Wang Xiaohai Li Jinghua Hu Ling Zhao Yikang Shi Source Type: research

Corrigendum Crocetin induces apoptosis of BGC ‑823 human gastric cancer cells
Mol Med Rep. 2023 Aug;28(2):151. doi: 10.3892/mmr.2023.13038. Epub 2023 Jun 23.ABSTRACTFollowing the publication of the above article, an interested reader drew to the authors' attention that Fig. 2 (showing morphological characteristics of cultured BGC‑823 cells as visualized by microscopic analysis) and Fig. 3 (showing crocetin‑induced apoptosis of the BGC‑823 cells) on p. 523 appeared to feature panels containing overlapping data. The authors re‑examined their original data, and realized that inadvertent errors were made during the compilation of these figures; specifically, the data shown in Fig. 2C (for the th...
Source: Molecular Medicine - June 23, 2023 Category: Molecular Biology Authors: Ke He Picheng Si Hanning Wang Usman Tahir Kaiyun Chen Jinfeng Xiao Xiaopeng Duan Rui Huang Guoan Xiang Source Type: research

Improved Antitumor Efficacy of a Dextran-based Docetaxel-Coupled Conjugate Against Triple-Negative Breast Cancer
CONCLUSION: This dual-drug C-DDD has the potential to become a candidate for clinical application through the optimization of the linker.PMID:37349996 | DOI:10.2174/1567201820666230622105503
Source: Current Drug Delivery - June 23, 2023 Category: Drugs & Pharmacology Authors: Hongshuai Lv Weiping Jia Peng Dong Jiaojiao Liu Si Wang Xiaohai Li Jinghua Hu Ling Zhao Yikang Shi Source Type: research

Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients
CONCLUSIONS: According to our analysis, the risk factors obesity and prevalence of CTCs are not associated and may represent independent prognostic factors.PMID:37336651 | DOI:10.1016/j.clbc.2023.05.011
Source: Clinical Genitourinary Cancer - June 19, 2023 Category: Cancer & Oncology Authors: Marie Tzschaschel Thomas W P Friedl Fabienne Schochter Sabine Sch ütze Arkadius Polasik Tanja Fehm Klaus Pantel Christian Schindlbeck Andreas Schneeweiss J örg Schreier Hans Tesch Ralf Lorenz Viktoria Aivazova-Fuchs Lothar H äberle Peter Fasching Wolfg Source Type: research

Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)
DISCUSSION: The already completed RAMIRIS phase II demonstrated feasibility and efficacy of FOLFIRI-Ram. Especially docetaxel-pretreated patients seemed to markedly benefit from FOLFIRI-Ram, with favorable response- and PFS rates and lower toxicity. This offers a rationale for the phase III trial. If the RAMIRIS III trial transfers and confirms the results, they will affect the current treatment guidelines, recommending the combination therapy of FOLFIRI-Ram for taxane-pretreated patients with advanced GEA.TRIAL REGISTRATION: NCT03081143 Date of registration: 13.11.2015.PMID:37337155 | DOI:10.1186/s12885-023-11004-z
Source: Cancer Control - June 19, 2023 Category: Cancer & Oncology Authors: Sylvie Lorenzen Alix Schwarz Claudia Pauligk Eray Goekkurt Gertraud Stocker Jorge Riera Knorrenschild Gerald Illerhaus Tobias Dechow Markus Moehler Jean-Charles Moulin Daniel Pink Michael Stahl Marina Schaaf Thorsten Oliver Goetze Salah-Eddin Al-Batran Source Type: research

Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy
Biomed Pharmacother. 2023 Jun 15;165:115023. doi: 10.1016/j.biopha.2023.115023. Online ahead of print.ABSTRACTDual-receptor targeted (DRT) nanoparticles which contain two distinct targeting agents may exhibit higher cell selectivity, cellular uptake, and cytotoxicity toward cancer cells than single-ligand targeted nanoparticle systems without additional functionality. The purpose of this study is to prepare DRT poly(lactic-co-glycolic acid) (PLGA) nanoparticles for targeting the delivery of docetaxel (DTX) to the EGFR and PD-L1 receptor positive cancer cells such as human glioblastoma multiform (U87-MG) and human non-small...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 17, 2023 Category: Drugs & Pharmacology Authors: Fakhrossadat Emami Ramesh Duwa Asmita Banstola Seon Min Woo Taeg Kyu Kwon Simmyung Yook Source Type: research

Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis
CONCLUSION: Addition of prostate radiotherapy to ADT in cN1M0 prostate cancer yielded improved disease control and overall survival independent of other tumour and treatment factors.PMID:37330057 | DOI:10.1016/j.radonc.2023.109746
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - June 17, 2023 Category: Radiology Authors: Thiraviyam Elumalai Priyamvada Maitre Robin Portner Neethu Billy Graham Mariam Tom Young Simon Hughes Kanchana Wickramasinghe Rajanee Bhana Muhammad Sabar Kamalram Thippu Jayaprakash Hitesh Mistry Peter Hoskin Ananya Choudhury Source Type: research

Dual receptor specific nanoparticles targeting EGFR and PD-L1 for enhanced delivery of docetaxel in cancer therapy
Biomed Pharmacother. 2023 Jun 15;165:115023. doi: 10.1016/j.biopha.2023.115023. Online ahead of print.ABSTRACTDual-receptor targeted (DRT) nanoparticles which contain two distinct targeting agents may exhibit higher cell selectivity, cellular uptake, and cytotoxicity toward cancer cells than single-ligand targeted nanoparticle systems without additional functionality. The purpose of this study is to prepare DRT poly(lactic-co-glycolic acid) (PLGA) nanoparticles for targeting the delivery of docetaxel (DTX) to the EGFR and PD-L1 receptor positive cancer cells such as human glioblastoma multiform (U87-MG) and human non-small...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 17, 2023 Category: Drugs & Pharmacology Authors: Fakhrossadat Emami Ramesh Duwa Asmita Banstola Seon Min Woo Taeg Kyu Kwon Simmyung Yook Source Type: research

Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis
CONCLUSION: Addition of prostate radiotherapy to ADT in cN1M0 prostate cancer yielded improved disease control and overall survival independent of other tumour and treatment factors.PMID:37330057 | DOI:10.1016/j.radonc.2023.109746
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - June 17, 2023 Category: Radiology Authors: Thiraviyam Elumalai Priyamvada Maitre Robin Portner Neethu Billy Graham Mariam Tom Young Simon Hughes Kanchana Wickramasinghe Rajanee Bhana Muhammad Sabar Kamalram Thippu Jayaprakash Hitesh Mistry Peter Hoskin Ananya Choudhury Source Type: research

Androgen receptor knockdown enhances prostate cancer chemosensitivity by down ‐regulating FEN1 through the ERK/ELK1 signalling pathway
ConclusionCollectively, our studies demonstrate that AR knockdown improves the DTX sensitivity of prostate cancer cells by downregulating FEN1 through the ERK/ELK1 signalling pathway.
Source: Cancer Medicine - June 16, 2023 Category: Cancer & Oncology Authors: Weijie Xie, Shulin Li, Huan Guo, Jiawei Zhang, Menjiang Tu, Rui Wang, Bingling Lin, Yuqi Wu, Xiangwei Wang Tags: RESEARCH ARTICLE Source Type: research